GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (FRA:ZK70) » Definitions » 3-Year EBITDA Growth Rate

Conduit Pharmaceuticals (FRA:ZK70) 3-Year EBITDA Growth Rate : -61.00% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Conduit Pharmaceuticals 3-Year EBITDA Growth Rate?

Conduit Pharmaceuticals's EBITDA per Share for the three months ended in Dec. 2024 was €-0.74.

During the past 12 months, Conduit Pharmaceuticals's average EBITDA Per Share Growth Rate was -506.60% per year. During the past 3 years, the average EBITDA Per Share Growth Rate was -61.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 4 years, the highest 3-Year average EBITDA Per Share Growth Rate of Conduit Pharmaceuticals was -61.00% per year. The lowest was -61.00% per year. And the median was -61.00% per year.

Competitive Comparison of Conduit Pharmaceuticals's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Conduit Pharmaceuticals's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Conduit Pharmaceuticals's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Conduit Pharmaceuticals's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Conduit Pharmaceuticals's 3-Year EBITDA Growth Rate falls into.


;
;

Conduit Pharmaceuticals 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Conduit Pharmaceuticals  (FRA:ZK70) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Conduit Pharmaceuticals 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Conduit Pharmaceuticals's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Conduit Pharmaceuticals Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Conduit Pharmaceuticals Inc (FRA:ZK70) » Definitions » 3-Year EBITDA Growth Rate
Comparable Companies
PTN ENSC SPRB CMND IBO SILO CELZ SIGY GTBP AIMI VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
CDT:USA
Address
4581 Tamiami Trail North, Suite 200, Naples, FL, USA, 34103
Website
https://www.conduitpharma.com
Conduit Pharmaceuticals Inc is a clinical-stage specialty biopharmaceutical company that was formed to facilitate the development and commercialization of clinical assets that have not been or are not being prioritized by biopharmaceutical companies to develop pharmaceutical products that meet the unmet medical needs of patients. The Company's current development pipeline includes a glucokinase activator, which is Phase II ready for autoimmune diseases including uveitis, Hashimoto's Thyroiditis, preterm labor, and renal transplant rejection. The Company's development pipeline also includes a potent, irreversible inhibitor of human Myeloperoxidase (MPO) that has the potential to treat idiopathic male infertility.

Conduit Pharmaceuticals Headlines

No Headlines